TORONTO, July 3, 2019 /CNW/ - Kevin Sullivan, Chief Executive Officer, Appili Therapeutics Inc. (APLI), joined Tim Babcock, Managing Director, Capital Formation, TSX Venture Exchange, to open the market. Headquartered in Halifax, Nova Scotia, Appili is a biopharmaceutical company focused on the acquisition and development of novel treatments targeting unmet needs in infectious disease. Appili Therapeutics Inc. commenced trading on TSX Venture Exchange on June 25, 2019.
